

Please type a plus sign (+) inside this box → +

8/16/04

FW
PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/719,007
		Filing Date	November 20, 2003
		First Named Inventor	JOHNSON, RANDOLPH MELLUS
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8	Attorney Docket Number	DURE-007CON2

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> POSTCARD
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	
SB08a Form	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36.513 BOZICEVIC, FIELD & FRANCIS LLP
Signature	
Date	August 13, 2004

EXPRESS MAIL LABEL NO. EV 462737715 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 462737715 US

INFORMATION DISCLOSURE STATEMENT		
Address to:	Attorney Docket	DURE-007CON2
Mail Stop	First Named Inventor	JOHNSON, RANDOLPH MELLUS
Commissioner for Patents	Application Number	10/719,007
P.O. Box 1450	Confirmation No.	9101
Alexandria, VA 22313-1450	Filing Date	November 20, 2003
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Title:	"DEVICES AND METHODS FOR PAIN MANAGEMENT"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in parent application serial number 10/306,727 filed 11/26/2002 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. DURE-007CON2 may be charged thereon.


Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By:


Carol L. Francis
Registration No. 36,513

Date: August 13, 2004

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/719,007
Sheet	1	of	6	Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Group Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	DURE-007CON2

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		Re. 36,547		Crain et al.	02-01-00
		4,681,560		Schulte et al.	07-21-1987
		4,692,147		Duggan	09-08-1987
		5,798,114		Elsberry et al.	08-25-1998
		3,141,823		Jan Janssen et al.	07-21-1964
		3,760,984		Theeuwes	09-25-1973
		3,845,770		Theeuwes et al.	11-05-1974
		3,916,899		Theeuwes et al.	11-04-1975
		3,923,426		Theeuwes	12-02-1975
		3,987,790		Eckenhoff et al.	10-26-1976
		3,995,631		Higuchi et al.	12-07-1976
		3,998,834		Janssen et al.	12-21-1976
		4,016,880		Theeuwes et al.	04-12-1976
		4,036,228		Theeuwes	07-19-1977
		4,111,202		Theeuwes	09-05-1978
		4,111,203		Theeuwes	09-05-1978
		4,167,574		Janssens	09-11-1979
		4,203,440		Theeuwes	05-20-1980
		4,203,442		Michaels	05-20-1980

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/719,007
Sheet	2	Of	6	Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Group Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	DURE-007CON2

U.S. PATENT DOCUMENTS						Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
		4,210,139		Higuchi	07-01-1980		
		4,327,725		Cortese et al.	05-04-1982		
		4,360,019		Portner et al.	11-23-1982		
		4,487,603		Harris	12-11-1984		
		4,576,951		Rovati et al.	03-18-1986		
		4,582,835		Lewis et al.	04-15-1986		
		4,627,850		Deters et al..	12-09-1986		
		4,725,852		Gamblin et al..	02-16-1988		
		4,769,372		Kreek	09-06-1988		
		4,781,924		Lee et al.	11-01-1988		
		6,245,351		Nara et al.	06-01-2001		
		4,588,580		Gale et al.	05-13-1999		
		6,203,813		Gooberman	03-20-2001		
		4,865,845		Eckenhoff et al.	09-12-1989		
		5,057,318		Magruder et al.	10-15-1991		
		5,059,423		Magruder et al.	10-22-1991		
		5,112,614		Magruder et al.	05-12-1992		
		5,137,727		Eckenhoff	08-11-1992		
		5,180,716		Yaksh et al.	01-19-1993		
		5,187,177		Garzaran	02-16-1993		
		5,234,692		Magruder et al.	08-10-1993		
		5,234,693		Magruder et al.	08-10-1993		
		5,346,903		Ackerman et al.	09-13-1994		
		5,356,635		Raman et al.	10-01-1994		
		5,451,408		Mezei et al..	09-19-1995		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	Of	6	Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Group Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	DURE-007CON2

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,472,943		Crain et al.	12-05-95	
		5,486,362		Kitchell et al.	01-23-1996	
		5,487,739		Aebischer et al.	01-30-1996	
		5,512,578		Crain et al.	04-30-96	
		5,580,876		Crain et al.	12-03-96	
		5,633,000		Grossman et al.	05-27-1997	
		5,660,854		Haynes et al.	08-26-1997	
		5,672,167		Athayda et al.	09-30-1997	
		5,729,396		Dudley et.al	03-17-1998	
		5,747,058		Tipton et al.	05-05-1998	
		5,767,125		Crain et al.	06-16-98	
		5,798,114		Elsberry et al.	08-25-98	
		5,980,927		Nelson et. al..	11-09-1999	
		5,985,305		Peery et al.	11-16-1999	
		5,858,388		Grossman et al.	01-12-1999	
		6,096,756		Crain et al.	08-01-00	
		6,436,091		Hamer et al.	08-20-2002	
		6,541,021		Johnson et al.	04-01-2003	
		6,689,373		Johnson et al.	02-10-2004	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	Of	6	Attorney Docket Number	DURE-007CON2

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
	WO	99/36071		Lee et al.	07-22-1999	
	WO	97/49391		Sackler et al.	12-31-1997	
	WO	97/27840		Perry et al.	08-07-1997	
	WO	98/51246	A	Elkhoury et al.	11-19-1998	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Ahmedzai (1997), "New approaches to pain control in patients with cancer." <i>Eur. J. Cancer</i> , 33(6):S8-S14.				
		Anderson et al.. (1998), "Alternate routes of opioid administration in palliative care: pharmacologic and clinical concerns." <i>J. Pharmaceut. Care Pain Sympt. Control</i> , 6:5-21.				
		Bansinath, et al.. (1989). "Hyperglycemia does not modify the pupillary effects of μ and κ opiate Agonists in mice" <i>J. Ocular Pharmacology</i> , Vol. 5(1): 33-43.				
		Bruera et al.. (1987). "Use of the subcutaneous route of the administration of narcotics in patients with cancer pain" <i>Cancer</i> , Vol. 62(2): 407-411.				
		Cherny et al.. 1995). "Opioid pharmacotherapy in the management of cancer pain" <i>Cancer</i> , Vol. 76(7): 1283-1293.				
		Clotz et al.. (1991). "Clinical uses of fentanyl, sufentanil, and alfentanil" <i>Clinical Pharmacy</i> , Vol. 10: 581-593.				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	5	of	6	Attorney Docket Number	DURE-007CON2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Coda <i>et al.</i> (1997). "Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation" <i>Pain</i> , Vol. 72: 333-346.			
		Coyle <i>et al.</i> (1994), "Subcutaneous opioid infusions at home." <i>Oncology</i> , 8:21-27.			
		Crane (1994). "Intermittent subcutaneous infusion of opioids in hospice home care: An affective, economical, manageable option" <i>Am. J. Hospice & Palliative Care</i> , Vol. Jan/Feb: 8-12.			
		Dhasmana <i>et al.</i> (1987). "Gastrointestinal transit following intrathecal or subcutaneous narcotic analgesics" <i>Arch. Int. Pharmacodyn.</i> , Vol. 286: 152-161.			
		Fine (1997), "Fentanyl in the treatment of cancer pain." <i>Sem. Oncol.</i> , 24(16):S16-S27.			
		Finley (1990), "Pain management with spinally administered opioids." <i>Am. J. Hosp. Pharm.</i> , 47(1):S14-S17.			
		Fuginaga <i>et al.</i> (1988). "Reproductive and teratogenic effects of sufentanil and alfentanil in Sprague-Dawley rats" <i>Anesth Analg</i> , Vol. 67: 166-169.			
		Geller <i>et al.</i> (1993). "A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery" <i>Anesth Analg</i> , Vol. 76: 1243-1250.			
		Jeal <i>et al.</i> (1997), "Transdermal fentanyl. A review of its pharmacologic properties and therapeutic efficacy in pain control." <i>Drugs</i> , 53:109-138.			
		Kerr <i>et al.</i> (1988), "Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients." <i>Ann. Intern. Med.</i> , 108:554-557.			
		Kingery (1997), "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes." <i>Pain</i> , 73:123-139.			
		Leelanutakit (1996). "Management of cancer-related pain with transdermal fentanyl" <i>J. Med. Assoc. Thai</i> , Vol. 79(6): 341-346.			
		Martin <i>et al.</i> (1983), "Epidural and intrathecal narcotics." <i>Can. Anaesth. Soc. J.</i> , 30:662-673.			
		Moulin <i>et al.</i> (1992). "Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use" <i>Can. Med. Assoc. J.</i> , Vol. 146(6): 891-897.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	6	of	6	Attorney Docket Number	DURE-007CON2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Mucha <i>et al.</i> (1990). "Parker and Radow test of drug withdrawal aversion: Opposite effect in rats chronically infused with sufentanil or amphetamine" <i>Pharmacology Biochem. & Behavior</i> , Vol. 35: 219-224.
		Paix <i>et al.</i> (1995). "Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management" <i>Pain</i> , Vol. 3: 263-269.
		Satterlee (1991). "Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride" <i>Clinical Pharmacy</i> , Vol. 10: 635-637.
		Shaw (1993), "Treatment of intractable cancer pain by electronically controlled parenteral infusion of analgesic drugs." <i>Cancer</i> , 72:3416-3425.
		Skaer (1993), "Management of pain in the cancer patient." <i>Clin. Ther.</i> , 15:638-649.
		Slattery <i>et al.</i> (1985), "Newer methods of delivery of opiates for relief of pain." <i>Drugs</i> , 30:539-551.
		Sjøgren <i>et al.</i> (1994). "Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists" <i>Pain</i> , Vol. 59: 313-316.
		Taverne <i>et al.</i> (1992). "Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdominal surgery" <i>Clin. Pharmacokinet.</i> , Vol. 23(3): 231- 237.
		Van den Hoogen <i>et al.</i> (1987). "Epidural and subcutaneous morphine, meperidine (pethidine), fentanyl and sufentanil in the rat: Analgesia and other <i>in vivo</i> pharmacologic effects" <i>Anesthesiology</i> , Vol. 66: 186-194.
		Van den Hoogen <i>et al.</i> (1988). "Respiratory effects of epidural and subcutaneous morphine, meperidine (pethidine), fentanyl and sufentanil in the rat" <i>Anesth Analg</i> , Vol. 67: 1071-1078.
		Vertafridda <i>et al.</i> (1987), "Intraspinal morphine for cancer pain." <i>Acta Anaesthesiol Scand.</i> , 31(85):47-53.
		Wagner <i>et al.</i> (1997). "Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients" <i>Clin. Pharmacokinet.</i> , Vol. 33(6): 426-453.
		Willens <i>et al.</i> (1993). "Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil" <i>Heart & Lung</i> , Vol. 22(3): 239-251.
		Zeiler <i>et al.</i> (1991). "Kontinuierliche peridurale sufentanil-applikation zur postoperativen analgesie" <i>Anaesthesia</i> , Vol. 40: 543-548.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.